🫀 Semaglutide’s Multisystem Benefits Confirmed: Major Meta-Analysis

🔥 Main in 3 points

• Semaglutide reduced MACE by 16% (RR 0.84), resolved MASH in 63% (RR 1.84), and protected kidneys (HR 0.76).
• HbA1c dropped by 1.5% and weight by 12.4 kg; benefit seen across CV, hepatic, and renal endpoints.
• No increase in psychiatric or cancer risk reported.

🧪 Context

Systematic review/meta-analysis (35 trials, n=36,847, >24-week follow-up) of semaglutide (≥0.5 mg weekly SC, ≥7 mg PO) vs. placebo/active comparator, adults across 12 domains.

📍 Practical significance

Clinicians should consider semaglutide as a comprehensive, disease-modifying therapy for metabolic disease (not only diabetes/obesity): its CV, hepatic, renal, and weight benefits substantially broaden eligible populations. Discuss multisystem benefits in shared decision-making.

🔗 PubMed | DOI

🧾 Semaglutide discontinuation: What to prepare for

✅ Do

• Counsel patients before stopping GLP-1RAs like semaglutide on high risk of weight regain (mean +5.6 kg in obesity, +2 kg in T2D).
• Monitor HbA1c and weight; anticipate HbA1c rise (~0.6% in T2D).
• Consider long-term/indefinite duration for maximal benefit, especially after substantial weight loss.

⚠️ With caution

• Expect greater rebound with longer follow-up (>26 weeks) and after semaglutide vs. liraglutide.
• Monitor BP, waist circumference—both deteriorate post-cessation.

🚫 Avoid

• Abrupt discontinuation unless medically necessary.

🔗 PubMed | DOI

🫀 Semaglutide safe peri-thrombectomy—possible neuro benefit in no-thrombolysis LVO stroke

🧪 What was studied

RCT (phase 2), n=140, semaglutide 0.5mg SC before and 1 week after EVT vs. standard care for disabling large vessel occlusion (LVO) stroke. Primary: favorable 90-day mRS (0–2).

📈 Key results

• In overall LVO population: similar rates of good outcome (RR 1.05; NS).
• No-IVT subgroup: semaglutide group had higher rate of good recovery (65% vs. 44%; RR 1.18, 95%CI 1.02–1.36).
• No semaglutide-attributed SAEs.

📍 What this changes in practice

Semaglutide may be safely started peri-EVT for LVO stroke—even in acute phase. In patients not receiving IV thrombolysis, adjunctive semaglutide may improve functional recovery (needs phase 3 confirmation).

🔗 PubMed | DOI

⚠️ Endoscopic Safety Alert: Residual Gastric Content with Semaglutide Use

🧪 Context

Retrospective study, n=144, patients on semaglutide/tirzepatide >6 months undergoing EGD; compared to 132 on therapy <6 months.

📊 Numbers

• 11 of 12 (92%) patients on >6 months showed residual gastric content, despite standard fasting protocol (p<0.001).
• No complications reported, but risk for aspiration remains theoretical.

📍 Actions

For patients on semaglutide/tirzepatide >6 months, anticipate delayed gastric emptying and consider alternative fasting/procedure protocols or additional precautions. Communicate with endoscopy teams pre-procedure.

🔗 PubMed | DOI

🩸 Mirtazapine may help mitigate semaglutide GI intolerance in older adults

❓ Practice question

Can mirtazapine be used to manage GLP-1RA (semaglutide)-induced GI side effects in elderly, enabling dose escalation?

✅ Study answer

Case report: 72-year-old on semaglutide with severe GI AEs allowing only low dose. After starting mirtazapine, GI side effects improved, permitting continued semaglutide titration. Additional: improved mood, sleep, no mirtazapine-related AEs.

📍 How to apply

Consider low-dose mirtazapine in older adults with persistent GI intolerance to semaglutide when benefit of continued therapy is compelling and psychiatric profile favors its use. Monitor for additive side effects.

🔗 PubMed | DOI